TrialMultiple sclerosis (Houndmills, Basingstoke, England)2019

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.

Mark A Agius et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.